Upcoming Event: Live Q&A with Long-Term Mesothelioma Survivors on December 10 at 7 p.m. EST. Reserve Your Spot

Biphasic Mesothelioma

Fact Checked

Biphasic mesothelioma is a cancer caused by asbestos exposure. Malignant biphasic tumors contain a combination of epithelioid and sarcomatoid cells. Symptoms of biphasic mesothelioma can include a dry cough, shortness of breath and pleural effusion. Biphasic mesothelioma is sometimes known as mixed mesothelioma.

Biphasic mesothelioma is explained by Karen Selby, RN.
Biphasic mesothelioma is explained by Karen Selby, RN.
Jump to a Topic:

What Is Biphasic Mesothelioma?

Mesothelioma is known as biphasic when tumors contain a combination of epithelial and sarcomatoid cells. Like all other cell types of mesothelioma, asbestos exposure is the leading cause of the disease.

The life expectancy of patients with biphasic mesothelioma varies because prognosis depends on the ratio of epithelial and sarcomatoid cells.

The larger the percentage of sarcomatoid cells, the poorer the prognosis. This cell type is more common among pleural patients than peritoneal patients.

Biphasic is the second most common mesothelioma cell type.

  • Epithelial mesothelioma, also known as epithelioid, is the most common and the easiest to treat.
  • The sarcomatoid cell type accounts for 10% to 20% of cases and is more resistant to treatment.
  • Prognosis and life expectancy for biphasic mesothelioma depends on the ratio of epithelial and sarcomatoid cells.

Understanding the characteristics and diagnosis of this type of mesothelioma can help you make informed treatment decisions with your doctor. The study of these cells is known as mesothelioma histology.

Characteristics of Biphasic Mesothelioma

In biphasic mesothelioma cases, epithelioid cells and sarcomatoid cells can exist close together. They can also appear within separate areas of a tumor.

Areas of epithelial cells, usually composed of solid and tubopapillary cells (which are epithelial subtypes), are found scattered among sarcomatoid cells. The proportion of epithelial and sarcomatoid cells can vary greatly.

Cell Behavior and Prevalence

Incidence rates show nearly 30% of pleural mesothelioma tumors and 25% of peritoneal tumors are biphasic.

However, many pathologists believe the cell prevalence of biphasic mesothelioma would be higher if more areas of mesothelioma tumors were sampled and analyzed. Pathologists are experts in the field of pathology, which is the study of diseased tissue to diagnose conditions such as cancer. The pathologist is the doctor who reviews biopsies.

The cell behavior of a biphasic mesothelioma depends on which cell type is more prevalent.

Doctor talking to patients

Connect with a Top Mesothelioma Doctor

We've helped thousands of people affected by mesothelioma find the best treatments.

Get Started Now

Diagnosing the Biphasic Cell Type

The biphasic cell type can be difficult to detect and diagnose.

Mesothelioma cell types are important to detect because some clinical trials and treatments target specific cell types.

The characteristics of your cell type do not affect your symptoms. However, they may affect your life expectancy, according to a 2017 study published in Lung Cancer International.

On average, epithelial mesothelioma patients survive 200 days longer than the other types.

During a key diagnostic test called a biopsy, doctors may collect only a small sample of tissue to study in the lab.

Biphasic mesothelioma cells

Taking samples from just one location offers a limited view of the type and amount of mesothelioma cells involved.

Doctors can make a more accurate mesothelioma diagnosis by taking tissue samples from several parts of the tumor. Determining the specific cell type is important to the diagnostic process because it can affect your treatment options and prognosis.

Preventing a Misdiagnosis

Doctors use advanced tests such as immunohistochemistry to distinguish biphasic mesothelioma from other diseases that are easily confused with this cancer. This technique can detect certain proteins, revealing the specific type of abnormal cells.

Quick Fact:

The diagnostic process can be harder for biphasic patients since epithelioid and sarcomatoid cells must be detected.

With this information, doctors can rule out common misdiagnoses, including cancers such as synovial sarcoma and carcinosarcoma.

A 2011 study published in the Journal of Thoracic Oncology found the biphasic type can be misdiagnosed after a biopsy. A total of 83 patients in the study were confirmed to have this type of pleural cancer after undergoing an extensive surgical procedure called an extrapleural pneumonectomy.

However, only 26% of those patients had been originally diagnosed with this subtype. The authors explained biphasic mesothelioma can be more accurately diagnosed following surgery.

The initial diagnostic methods included thoracoscopy, thoracotomy, computerized tomography and other biopsy methods.

Biphasic Mesothelioma Treatment

Patients with the biphasic mesothelioma cell type may not be considered for an aggressive treatment plan as would patients with the epithelioid type.

The reason is that biphasic carries a slightly poorer prognosis than epithelioid. However, treatment is not completely based on cell type.

Most patients undergo one or more of these common therapies:

  • Surgery
  • Chemotherapy
  • Radiation

Treatment may depend more on the stage and location of the tumor than the cell type involved.

Clinical trials are testing new drugs and therapies specifically for mesothelioma patients with sarcomatoid or biphasic tumors.

For example, a phase II/III clinical trial is investigating an anti-cancer enzyme on sarcomatoid and biphasic mesothelioma tumors. Known as ADI-PEG 20 (pegylated arginine deiminase), the enzyme significantly improved survival of sarcomatoid patients in its phase I trial.

Create a Free Personalized Mesothelioma Guide

Were you diagnosed with mesothelioma?

Biphasic Prognosis and Life Expectancy

The prognosis for biphasic mesothelioma varies depending on the ratio of epithelial and sarcomatoid cells present in each case.

Quick Fact:

The more epithelial cells you have in a biphasic mix, the better your prognosis may be. How much better may amount to only a few months depending on the case.

In one study involving 85 pleural mesothelioma patients with a variety of cellular subtypes, people with the biphasic cell type had an average survival of about 15 months. Those with the epithelial subtype displayed the highest average survival — more than 22 months.

The researchers observed slightly better survival among biphasic patients whose tumors had mostly epithelial cells, compared to those with mostly sarcomatoid cells.

While the survival advantage was only 16 days, sarcomatoid cells are less responsive to treatment than epithelial cells. As a result, biphasic patients with a lower number of sarcomatoid cells tend to see better results from treatment.

In another study, researchers observed the survival of 255 mesothelioma patients. Seventeen of the patients were diagnosed with desmoplastic mesothelioma, which is a cell subtype of sarcomatoid mesothelioma. Of those 17 patients, 11 had pure sarcomatoid tumors while six had biphasic tumors. Patients with pure sarcomatoid tumors survived 5.8 months and patients with biphasic tumors survived 6.8 months.

Epithelial cells in the biphasic tumors likely contributed to the one-month survival advantage observed in the biphasic patients.

The poorer prognosis may partially be influenced by PD-L1 levels. In a 2019 study published in Clinical Lung Cancer, pleural mesothelioma patients with sarcomatoid and biphasic cells had higher levels of PD-L1, which is associated with shorter survival.

Another factor contributing to the poorer prognosis of biphasic mesothelioma is that sarcomatoid cells tend to spread faster than epithelial cells.

Biphasic tumors with a high ratio of sarcomatoid cells may spread quicker and result in shorter life expectancy.

Get the Compensation You Deserve

File a Claim
Asbestos.com Mesothelioma Packet

Learn About Top Mesothelioma Treatments

Get Your Guide

Immunotherapy & Mesothelioma Clinical Trials

Find Treatment

Registered Nurse and Patient Advocate

Karen Selby joined Asbestos.com in 2009. She is a registered nurse with a background in oncology and thoracic surgery and was the regional director of a tissue bank before becoming a Patient Advocate at The Mesothelioma Center. Karen has assisted surgeons with thoracic surgeries such as lung resections, lung transplants, pneumonectomies, pleurectomies and wedge resections. She is also a member of the Academy of Oncology Nurse & Patient Navigators.

Walter Pacheco, Managing Editor at Asbestos.com
Edited by
Dr. Daniel Landau, mesothelioma specialist & medical content reviewer for Asbestos.com
Medical Review By

8 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.

  1. Brosseau, S. et al. (2019). Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/31279641
  2. American Cancer Society. (2018, November 16). About Malignant Mesothelioma.
    Retrieved from: https://www.cancer.org/cancer/malignant-mesothelioma/about/malignant-mesothelioma.html
  3. Kao, S.C. et al. (2011). Accuracy of Diagnostic Biopsy for the Histological Subtype of Malignant Pleural Mesothelioma.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/21266919
  4. Dodson, R. & Hammar, S. Asbestos: Risk Assessment, Epidemiology, and Health Effects. Taylor & Francis: Boca Raton, 2006.
  5. Galateau-Salle, F. Pathology of Malignant Mesothelioma. Springer-Verlag London Limited: London, 2006.
  6. Pass, I., Vogelzang, N. & Carbone, M. Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Transitional Therapies. Springer: New York, 2005.
  7. Trupiano, J.K. et al. (2004). Diffuse Malignant Mesothelioma of the Peritoneum and Pleura, analysis of markers.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/14976533
  8. Bruce, W., Robinson, A. & Chahinian, P. Mesothelioma. Informa Health Care, 2002.
  •  
  •  
  •  

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified October 15, 2020

Chat live with a patient advocate now